UBS Group’s Meridian Bioscience Inc VIVO Stock Holding History

UBS Group’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-1,400	Closed	-$23K	–	9561
2014 Q4	$23K	Buy	+1,400	New	+$24K	﹤0.01%	7460

Other funds holding VIVO

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

UBS Group's VIVO Position: Q1 2023 in Review

UBS Group sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 50,739 shares — an estimated $1.69M sold.

UBS Group first reported a position in VIVO in Q4 2014 and held it in 33 quarters. The position peaked at $7.78M in Q2 2017. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

UBS Group reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
UBS Group sold 50,739 Meridian Bioscience Inc shares in Q1 2023, an estimated $1.69M.
UBS Group first reported a position in Meridian Bioscience Inc in Q4 2014 and held it in 33 quarters.
UBS Group's Meridian Bioscience Inc position peaked at $7.78M in Q2 2017.
2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.